Galectin-3 levels are elevated following nintedanib treatment
Background and Aims: Idiopathic pulmonary fibrosis (IPF) is a common and severe form of pulmonary fibrosis. Nintedanib, a triple angiokinase inhibitor, is approved for treating IPF. Galectin 3 (Gal-3) activates a variety of profibrotic processes. Currently, the Gal-3 inhibitor TD139 is being tested...
Guardat en:
| Autors principals: | , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
SAGE Publishing
2020-11-01
|
| Col·lecció: | Therapeutic Advances in Chronic Disease |
| Accés en línia: | https://doi.org/10.1177/2040622320968412 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|